Evidence map›Paper›PMID 22624709›Full record

ArticleCancer cell2012

SMIP-016 in action: CD37 as a death receptor.

Lei Jin, John C Cambier

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Employing Piezoelectric MgAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lei JinDepartment of Immunology, University of Colorado School of Medicine and National Jewish Health Denver, Denver, CO 80206, USA.
John C CambierDepartment of Immunology, University of Colorado School of Medicine and National Jewish Health Denver, Denver, CO 80206, USA. Electronic address: cambierj@njhealth.org.
National Jewish Health · US

Funding

Molecular Mechanisms of Immune ToleranceT32AI074491 · NIAID · NATIONAL JEWISH HEALTH · PI CAMBIER, JOHN C, PELANDA, ROBERTA · 2009 to 2023
$4.1M
NIAID NIH HHS T32 AI074491
6 · The paper itself

Abstract

CD37 is a tetraspannin that triggers cell death and is a potential therapeutic target in cancers. In this issue of Cancer Cell, Lapalombella et al. show that CD37 is tyrosine phosphorylated following engagement by a bivalent engineered antibody fragment that binds CD37 and activates both SHP-1-dependent apoptotic signaling and PI3K-AKT-mediated survival signaling.

Identifiers

PMID22624709
PMCPMC4363110
OpenAlexW2073707409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.